Supplementary Materials

Supplementary Material for:

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Jeanne Tie,* Yuxuan Wang, Cristian Tomasetti, Lu Li, Simeon Springer, Isaac Kinde, Natalie Silliman, Mark Tacey, Hui-Li Wong, Michael Christie, Suzanne Kosmider, Iain Skinner, Rachel Wong, Malcolm Steel, Ben Tran, Jayesh Desai, Ian Jones, Andrew Haydon, Theresa Hayes, Tim J. Price, Robert L. Strausberg, Luis A. Diaz Jr., Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein,* Peter Gibbs*

*Corresponding author. Email: jeanne.tie{at}mh.org.au (J.T.); vogelbe{at}jhmi.edu (B.V.); peter.gibbs{at}mh.org.au (P.G.)

Published 06 July 2016, Sci. Transl. Med. 8, 346ra92 (2016)
DOI: 10.1126/scitranslmed.aaf6219

This PDF file includes:

  • Fig. S1. Recurrence-free survival in patients not treated with adjuvant chemotherapy stratified by postoperative CEA status.
  • Table S1. Relationship between postoperative ctDNA, postoperative CEA, and recurrence status for patients not treated with chemotherapy.
  • Table S2. Time-dependent predictive accuracy of postoperative ctDNA for recurrence at 5, 6, 12, 18, 24, 36, and 40 months.
  • Table S3. Serial circulating biomarker status and clinical characteristics of patients not treated with adjuvant chemotherapy who experienced recurrence.
  • Table S4. Serial circulating biomarker status and clinical characteristics of chemotherapy-treated patients who experienced recurrence.
  • Table S5. Genomic and clinical summary for all patients included in the final evaluable population.
  • Table S6. Panel of 15 genes used for identification of somatic mutations in tumor tissue.

[Download PDF]